



FOR IMMEDIATE RELEASE

25th September 2006

**OXFORD GENE TECHNOLOGY GRANTS MICROARRAY LICENSE TO
INVITROGEN FOR MICROARRAY SERVICES**

Oxford, September 25, 2006 - Oxford Gene Technology (OGT) and Invitrogen Corporation are pleased to announce the completion of a licence agreement granting Invitrogen access to one of OGT's "Southern array patents", the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.

The granted license will enable Invitrogen to offer DNA related microarray services, worldwide, from its US operations.

Sue Sutton, Vice President Licensing North America, at OGT said: "Successful discussions with Invitrogen have concluded with the granting of this license thus enabling a world class company such as Invitrogen to expand their service base and adding to OGT's growing portfolio of North American licensees."

Amy Butler, Vice President of Invitrogen's Gene Expression Profiling business, commented that, "Invitrogen continually strives to provide complete and optimised solutions to its customers in terms of both its products and its services. This agreement will enable Invitrogen to provide a more complete offering to its customers who are interested in microarray services."

The licence will remain valid for the patents' lifetime. Financial details were not disclosed.

- ENDS -

For further information, please contact:

At Oxford Gene Technology:

Nicola Booton-Mander, Marketing Manager

Oxford Gene Technology
Begbroke Science Park,
Sandy Lane, Yarnton
Oxford OX5 1PF
T: +44 1865 856352
F: +44 1865 842116
E: licensing@ogt.co.uk
W: www.ogt.co.uk

Media Enquiries:

Annabel Entress, 0207 886 8150 / a.entress@northbankcommunications.com

Sarah Jeffery, 0207 886 8150 / s.jeffery@northbankcommunications.com

Notes to editors

About Oxford Gene Technology

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip² family

The key focus areas of OGT include:

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation
2. **Development of innovative platform products** for clinical research and diagnostics
3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
4. **Scientific collaborations** to generate diagnostic biomarker intellectual property

For further information on OGT visit <http://www.ogt.co.uk/>

About Invitrogen Corporation

Invitrogen Corporation (Nasdaq:[IVGN](#) - [News](#)) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics and cell biology - placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987,

Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than \$1.2 billion in 2005. For more information, visit www.invitrogen.com.

- ENDS -